Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
SAWAI GROUP HOLDINGS Co., Ltd. ( (JP:4887) ) has provided an update.
Sawai Group Holdings Co., Ltd. has announced a financial provision for a loss on litigation related to a patent infringement settlement concerning its Teriparatide Subcutaneous Injection. The company will recognize a 4 billion yen expense in its financial results for the second quarter of the fiscal year ending March 31, 2026. Despite this expense, the company has maintained its previously announced dividend amounts, indicating a stable financial outlook.
The most recent analyst rating on (JP:4887) stock is a Hold with a Yen1980.00 price target. To see the full list of analyst forecasts on SAWAI GROUP HOLDINGS Co., Ltd. stock, see the JP:4887 Stock Forecast page.
More about SAWAI GROUP HOLDINGS Co., Ltd.
Sawai Group Holdings Co., Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of generic drugs. The company is known for its commitment to providing affordable and high-quality medication, primarily serving the Japanese market.
Average Trading Volume: 385,903
Technical Sentiment Signal: Hold
Current Market Cap: Yen185.6B
See more insights into 4887 stock on TipRanks’ Stock Analysis page.